Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
基本信息
- 批准号:8894367
- 负责人:
- 金额:$ 56.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAccountingAcquired Immunodeficiency SyndromeAdherenceAffectAfrican Traditional MedicineAllelesAnti-Retroviral AgentsAntiretroviral drug resistanceBloodCD4 Lymphocyte CountCaringCase-Control StudiesClinicClinicalConflict (Psychology)CountryDataDeath RateDoseDrug resistanceEnrollmentErythrocytesEuropeanFailureFrequenciesGenerationsGovernmentHIVHIV drug resistanceHIV-1HairHealthHospitalsInterviewLaboratoriesLamivudineLifeLogistic RegressionsMeasuresMedical RecordsMinorityModelingMonitorMorbidity - disease rateMutationNNRTI-resistanceNational Health ServicesNeurocognitiveNevirapineOutcomeParticipantPatient Self-ReportPatientsPatternPersonsPharmaceutical PreparationsPharmacy facilityPlasmaPopulationPopulation GeneticsPrevalencePrevalence StudyPreventionProbabilityProvinceQuestionnairesRegimenRegression AnalysisReportingResistanceResistance developmentResourcesRiskRisk FactorsRuralSamplingSourceSouth AfricaSouthern AfricaSpottingsStructureTenofovirTestingTimeTreatment FailureValidationVariantVertical Disease TransmissionViralVirusWomanantiretroviral therapybasecase controlclinically significantcohortcostdeep sequencingdesignexperiencefitnessfollow-upinterestmortalitymutantnext generation sequencingnon-nucleoside reverse transcriptase inhibitorsnovelpillpreventresistance mutationresponsesuccesstheoriestherapy adherencetransmission processtreatment adherencetreatment duration
项目摘要
DESCRIPTION (provided by applicant): Since the introduction in 2002 of government-sponsored antiretroviral therapy (ART) in South Africa in 2002, nearly 1 million patients have received ART, and the death rate from HIV/AIDS has declined. Although early accounts of treatment success reported high rates of adherence and viral suppression, rates of virologic failure (VF) have begun to approximate those observed in resource-rich countries. Because virologic monitoring is less frequent than in the US, there is more opportunity for resistance mutations to accumulate before VF is detected and ART switched to a 2nd-line regimen. As a result, the efficacy of 2nd-line therapy may be compromised. To date, there has not been a comprehensive study of the prevalence and risk factors associated with drug resistance in persons failing 1st-line ART in South Africa. Likewise, the effect of minority drug-resistant variants on the efficacy of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens has not been studied except in women who received single-dose nevirapine (NVP) for prevention of mother-to-child transmission of HIV-1. Because transmitted resistance remains rare in South Africa, drug- resistant minority variants detected in this population may be assumed to reflect the spontaneous generation of such mutants by the error-prone HIV-1 RT. We propose to study the patterns and predictors of HIV-1 drug resistance after VF of 1st-line ART and the clinical significance of minority drug-resistant minority variants in peri-urban and rural settings in KwaZulu-Natal (KZN), South Africa. Specific aims of this proposal are as follows: 1) To determine the red blood cell ARV levels associated with VF and HIV-1 drug resistance at the time of 1st-line ART failure in KZN; 2) To determine the risk factors for VF and HIV-1 drug resistance in rural and peri-urban settings in the KZN province, South Africa; 3) To determine the effect of spontaneously arising drug- resistant minority variants on the risk of VF in patients receiving 1st-line ART. Subjects starting ART will be enrolled from clinics in two settings in KZN-peri-urban and rural. The number and patterns of HIV drug resistance mutations for patients who experience virologic failure of a 1st-line regimen of TDF plus lamivudine and EFV or NVP will be compared to resistance patterns reported for subtype B virus. A case-control design will be used to identify risk factors for suboptimal adherence and virologic failure
with or without drug resistance in different settings in KZN province. The prevalence of minority drug resistant variants in the virus population will be determined in pre-treatment samples using allele-specific PCR and next-generation sequencing using the Illumina Solexa platform; the effect of these resistance mutations on the risk of virologic failure will be determined. Exploratory analyses will compare the frequency distribution of minority drug resistance mutations with the frequency predicted from population genetic theory to estimate the fitness cost of these mutations compared to the wildtype in the absence of drugs. The probability that a minority variant becomes fixed in the population and leads to resistance and VF will also be determined.
描述(申请人提供):自2002年在南非引入政府资助的抗逆转录病毒疗法(ART)以来,近100万患者接受了ART治疗,艾滋病毒/艾滋病死亡率下降。虽然早期的治疗成功报告了高依从率和病毒抑制率,但病毒学失败(VF)率已开始接近资源丰富国家的水平。由于病毒学监测频率低于美国,因此在检测到VF和ART转换为二线方案之前,耐药突变有更多的机会积累。因此,二线治疗的疗效可能会受到影响。迄今为止,尚未对南非一线抗逆转录病毒治疗失败者的耐药性流行率和相关风险因素进行全面研究。同样,少数耐药变异对非核苷类逆转录酶抑制剂(NNRTI)为基础的方案的疗效的影响尚未研究,但接受单剂量奈韦拉平(NVP)预防母婴传播HIV-1的女性除外。因为在南非传播的抗药性仍然很罕见,在这一人群中检测到的耐药少数变异体可能被认为反映了易出错的HIV-1 RT自发产生的这种突变体。我们建议研究一线ART VF后HIV-1耐药的模式和预测因素,以及夸祖鲁省城乡结合部少数耐药少数变异体的临床意义。南非,纳塔尔(KZN)。该提案的具体目标如下:1)确定KZN一线抗逆转录病毒治疗失败时与VF和HIV-1耐药性相关的红细胞ARV水平; 2)确定南非KZN省农村和城郊环境中VF和HIV-1耐药性的风险因素; 3)确定自发产生的耐药少数变异对接受一线ART的患者VF风险的影响。开始ART的受试者将从KZN城市周边和农村两个环境的诊所入组。将比较TDF+拉米夫定+EFV或NVP一线治疗方案病毒学失败患者的HIV耐药突变数量和模式与报告的B亚型病毒耐药模式。病例对照设计将用于确定次优依从性和病毒学失败的风险因素
在KZN省的不同环境中有或没有耐药性。将使用等位基因特异性PCR和下一代测序(使用Illumina Solexa平台)在治疗前样本中确定病毒群体中少数耐药变异的患病率;将确定这些耐药突变对病毒学失败风险的影响。探索性分析将比较少数耐药突变的频率分布与群体遗传学理论预测的频率,以估计这些突变在不存在药物的情况下与野生型相比的适应度成本。还将确定少数变异体在群体中固定并导致耐药性和VF的概率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel R. Kuritzkes其他文献
Ultrasensitive and long-lasting bioluminescence immunoassay for point-of-care viral antigen detection
用于即时检验病毒抗原检测的超灵敏和持久的生物发光免疫测定法
- DOI:
10.1038/s41551-025-01405-9 - 发表时间:
2025-05-30 - 期刊:
- 影响因子:26.600
- 作者:
Sungwan Kim;Giwon Cho;Jaebaek Lee;Khushi Doshi;Supriya Gharpure;Jisan Kim;Juyong Gwak;Joseph M. Hardie;Manoj K. Kanakasabapathy;Hemanth Kandula;Prudhvi Thirumalaraju;Younseong Song;Hui Chen;Daniel R. Kuritzkes;Jonathan Z. Li;Athe M. Tsibris;Hadi Shafiee - 通讯作者:
Hadi Shafiee
Dominant CD4sup+/sup T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV
在接受抗逆转录病毒疗法介导的人类免疫缺陷病毒感染者免疫恢复期间,占优势的 CD4+T 细胞受体保持稳定。
- DOI:
10.1016/j.xcrm.2023.101268 - 发表时间:
2023-11-21 - 期刊:
- 影响因子:10.600
- 作者:
Alexis Sponaugle;Ann Marie K. Weideman;Jolene Ranek;Gatphan Atassi;JoAnn Kuruc;Adaora A. Adimora;Nancie M. Archin;Cynthia Gay;Daniel R. Kuritzkes;David M. Margolis;Benjamin G. Vincent;Natalie Stanley;Michael G. Hudgens;Joseph J. Eron;Nilu Goonetilleke - 通讯作者:
Nilu Goonetilleke
Willingness to trade-off years of life for an HIV cure – an experimental exploration of affective forecasting
- DOI:
10.1186/s12981-024-00640-5 - 发表时间:
2024-08-06 - 期刊:
- 影响因子:2.500
- 作者:
Ilona Fridman;Nir Eyal;Karen A. Scherr;Judith S. Currier;Kenneth A. Freedberg;Scott D. Halpern;Daniel R. Kuritzkes;Monica Magalhaes;Kathryn I. Pollak;Peter A. Ubel - 通讯作者:
Peter A. Ubel
Daniel R. Kuritzkes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel R. Kuritzkes', 18)}}的其他基金
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
博茨瓦纳早期治疗儿童中三种广泛中和抗体和分析治疗中断的临床试验
- 批准号:
10764517 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
三特异性广泛中和抗体治疗期间的 HIV-1 动力学和进化
- 批准号:
10388267 - 财政年份:2021
- 资助金额:
$ 56.74万 - 项目类别:
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
三特异性广泛中和抗体治疗期间的 HIV-1 动力学和进化
- 批准号:
10599272 - 财政年份:2021
- 资助金额:
$ 56.74万 - 项目类别:
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
三特异性广泛中和抗体治疗期间的 HIV-1 动力学和进化
- 批准号:
10258850 - 财政年份:2021
- 资助金额:
$ 56.74万 - 项目类别:
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
一项临床试验,旨在评估广泛中和抗体 VRC01 对博茨瓦纳早期治疗儿童队列中 HIV 病毒库的影响以及维持抑制
- 批准号:
10092914 - 财政年份:2018
- 资助金额:
$ 56.74万 - 项目类别:
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
一项临床试验,旨在评估广泛中和抗体 VRC01 对博茨瓦纳早期治疗儿童队列中 HIV 病毒库的影响以及维持抑制
- 批准号:
10700262 - 财政年份:2018
- 资助金额:
$ 56.74万 - 项目类别:
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana
一项临床试验,旨在评估广泛中和抗体 VRC01 对博茨瓦纳早期治疗儿童队列中 HIV 病毒库的影响以及维持抑制
- 批准号:
10335240 - 财政年份:2018
- 资助金额:
$ 56.74万 - 项目类别:
A Pilot Clinical Trial for HIV-1 Eradication
根除 HIV-1 的试点临床试验
- 批准号:
9197496 - 财政年份:2015
- 资助金额:
$ 56.74万 - 项目类别:
A Pilot Clinical Trial for HIV-1 Eradication
根除 HIV-1 的试点临床试验
- 批准号:
8892586 - 财政年份:2015
- 资助金额:
$ 56.74万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 56.74万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别: